CLS (CHARTER LIFE SCIENCES) is an early stage life sciences venture capital investor.

CLS makes initial portfolio company investments in life sciences companies that are seeking capital to obtain initial proof-of-efficacy of their products (see Investment Criteria), and we continue to support our successful portfolio companies with follow on investments until they are acquired or go public.

Our team is led by four Managing Partners who have worked together to create and build life sciences companies for over twenty years. Our team brings extensive scientific, clinical, regulatory, operational and finance experience to each of our portfolio companies.

We play an active role in helping entrepreneurs build successful companies. Our time, energy and passion is devoted to building early stage life sciences opportunities. As a result, your company will be compared only against other early stage opportunities. So, at CLS, your early stage biotech medical device or health care information technology company will not be compared against a PIPE investment in an undervalued Phase III company, as an example. Early stage is what we do, and all we do.


We understand that early stage companies do not have all the answers and do not have all the data. We understand that many basic questions need investment capital to answer, and we understand that development plans and milestones are subject to lots of uncertainty and change. We understand what it takes to build a management team from scratch, and we invest in companies with little or no existing management. In short, we understand what it is to be an early stage entrepreneur, because each of us has been one.

Please look carefully at our investment criteria and our team, and if we are the type of partner that you would like to work with, please contact us.

In the News

Amaranth Medical, a privately held medical device company, announced the initiation of a clinical study of the Company’s latest-generation MAGNITUDE™ sirolimus-eluting bioresorbable scaffold (BRS) scaffold, which has a strut thickness in the sub-100-micron range. Dr. Antonio Colombo, director of the Hemodynamics Division at Ospedale San Raffaele in Milan, Italy and Dr. Juan F. Granada, executive director and chief innovation officer of the CRF-Skirball Center for Innovation will serve as co-primary investigators. “Cardiologists are really asking for thin-walled scaffolds displaying the performance, efficacy and safety profile of metallic drug eluting stents,” noted Dr. Juan F. Granada. “The introduction of [more]
Amaranth Medical, a privately held medical device company, announced that a presentation of the 9-month clinical and imaging results from the company’s FORTITUDE® sirolimus-eluting bioresorbable scaffold (BRS) took place during the First Report Investigations session at the Transcatheter Cardiovascular Therapeutics (TCT) 2016 scientific symposium on Monday, October 31st. Dr. Antonio Colombo, co-principal investigator and director of the Hemodynamics Division at Ospedale San Raffaele in Milan, Italy presented the main clinical and imaging findings from the 62 patients who received the FORTITUDE scaffold. “This study represents an important milestone for this technology, as it demonstrates not only the feasibility of delivery [more]